285 related articles for article (PubMed ID: 21376668)
1. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer.
Andorfer CA; Necela BM; Thompson EA; Perez EA
Trends Mol Med; 2011 Jun; 17(6):313-9. PubMed ID: 21376668
[TBL] [Abstract][Full Text] [Related]
2. Receptor-based predictors of response in breast cancer.
McGovern UB; Stebbing J
Future Oncol; 2009 Apr; 5(3):283-6. PubMed ID: 19374534
[No Abstract] [Full Text] [Related]
3. MicroRNAs in breast cancer pathogenesis.
Götte M
Minerva Ginecol; 2010 Dec; 62(6):559-71. PubMed ID: 21079577
[TBL] [Abstract][Full Text] [Related]
4. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.
Tang P; Wang J; Hicks DG; Wang X; Schiffhauer L; McMahon L; Yang Q; Shayne M; Huston A; Skinner KA; Griggs J; Lyman G
Cancer Invest; 2010 Nov; 28(9):978-82. PubMed ID: 20690804
[TBL] [Abstract][Full Text] [Related]
5. Novel targets for triple-negative breast cancer.
Carey LA
Clin Adv Hematol Oncol; 2011 Sep; 9(9):678-80. PubMed ID: 22402512
[No Abstract] [Full Text] [Related]
6. MiRNAs as biomarkers and therapeutic targets in cancer.
Heneghan HM; Miller N; Kerin MJ
Curr Opin Pharmacol; 2010 Oct; 10(5):543-50. PubMed ID: 20541466
[TBL] [Abstract][Full Text] [Related]
7. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
Diaz LK; Cryns VL; Symmans WF; Sneige N
Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
[TBL] [Abstract][Full Text] [Related]
8. [Endocrinology of breast cancer as a heterogeneous disease: a decade after the millennium].
Bershteĭn LM
Vopr Onkol; 2013; 59(3):292-8. PubMed ID: 23909028
[No Abstract] [Full Text] [Related]
9. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer.
Shi M; Guo N
Cancer Treat Rev; 2009 Jun; 35(4):328-34. PubMed ID: 19171434
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
11. Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients.
Ota D; Mimori K; Yokobori T; Iwatsuki M; Kataoka A; Masuda N; Ishii H; Ohno S; Mori M
Int J Oncol; 2011 Apr; 38(4):955-62. PubMed ID: 21271219
[TBL] [Abstract][Full Text] [Related]
12. DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer.
Germain DR; Graham K; Glubrecht DD; Hugh JC; Mackey JR; Godbout R
Breast Cancer Res Treat; 2011 May; 127(1):53-63. PubMed ID: 20499159
[TBL] [Abstract][Full Text] [Related]
13. miRNAs as molecular biomarkers of cancer.
Fabbri M
Expert Rev Mol Diagn; 2010 May; 10(4):435-44. PubMed ID: 20465498
[TBL] [Abstract][Full Text] [Related]
14. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
17. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
Generali D; Berruti A; Foroni C; Bazzola L; Andreis D; Allevi G; Bersiga A; Dogliotti L; Fox SB; Harris AL; Bottini A
J Natl Cancer Inst Monogr; 2011; 2011(43):67-70. PubMed ID: 22043044
[TBL] [Abstract][Full Text] [Related]
18. Molecular stratification of triple-negative breast cancers.
Perou CM
Oncologist; 2011; 16 Suppl 1():61-70. PubMed ID: 21278442
[TBL] [Abstract][Full Text] [Related]
19. [Gene expression analysis and its clinical use in breast tumors].
Semiglazov VF; Semiglazov VV; Moiseenko FV; Bogdanov AA; Boĭtsov VV; Viaz'min SV; Gorab DN; Chubenko VA; Brezhnev NV; Luk'ianchikova VS; Dubina MV
Vopr Onkol; 2013; 59(1):25-9. PubMed ID: 23805447
[No Abstract] [Full Text] [Related]
20. Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer.
Müller BM; Kronenwett R; Hennig G; Euting H; Weber K; Bohmann K; Weichert W; Altmann G; Roth C; Winzer KJ; Kristiansen G; Petry C; Dietel M; Denkert C
Diagn Mol Pathol; 2011 Mar; 20(1):1-10. PubMed ID: 21326033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
